Cell and Gene Therapy Biomanufacturing Market - Strategic Insights and Forecasts (2026-2031)

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

1. 2.1. Market Overview

2. 2.2. Market Definition

3. 2.3. Scope of the Study

4. 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

1. 3.1. Market Drivers

2. 3.2. Market Restraints

3. 3.3. Market Opportunities

4. 3.4. Porter’s Five Forces Analysis

5. 3.5. Industry Value Chain Analysis

6. 3.6. Policies and Regulations

7. 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. CELL AND GENE THERAPY BIOMANUFACTURING MARKET BY PRODUCT

1. 5.1. Introduction

2. 5.2. Reagents & Consumables

3. 5.3. Instruments & Equipment

4. 5.4. Software & Services

6. CELL AND GENE THERAPY BIOMANUFACTURING MARKET BY WORKFLOW

1. 6.1. Introduction

2. 6.2. Upstream Processing

3. 6.3. Downstream Processing

4. 6.4. Fill-Finish Operations

7. CELL AND GENE THERAPY BIOMANUFACTURING MARKET BY APPLICATION

1. 7.1. Introduction

2. 7.2. Oncology

3. 7.3. Rare & Genetic Diseases

4. 7.4. Cardiovascular Diseases

5. 7.5. Neurological Disorders

6. 7.6. Infectious Diseases

7. 7.7. Others

8. CELL AND GENE THERAPY BIOMANUFACTURING MARKET BY GEOGRAPHY

1. 8.1. Introduction

2. 8.2. North America

   1. 8.2.1. USA

   2. 8.2.2. Canada

   3. 8.2.3. Mexico

3. 8.3. South America

   1. 8.3.1. Brazil

   2. 8.3.2. Argentina

   3. 8.3.3. Others

4. 8.4. Europe

   1. 8.4.1. United Kingdom

   2. 8.4.2. Germany

   3. 8.4.3. France

   4. 8.4.4. Spain

   5. 8.4.5. Others

5. 8.5. Middle East and Africa

   1. 8.5.1. Saudi Arabia

   2. 8.5.2. UAE

   3. 8.5.3. Others

6. 8.6. Asia Pacific

   1. 8.6.1. China

   2. 8.6.2. India

   3. 8.6.3. Japan

   4. 8.6.4. South Korea

   5. 8.6.5. Indonesia

   6. 8.6.6. Thailand

   7. 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

1. 9.1. Major Players and Strategy Analysis

2. 9.2. Market Share Analysis

3. 9.3. Mergers, Acquisitions, Agreements, and Collaborations

4. 9.4. Competitive Dashboard

10. COMPANY PROFILES

1. 10.1. Lonza Group

2. 10.2. Thermo Fisher Scientific

3. 10.3. Merck KGaA

4. 10.4. Danaher Corporation

5. 10.5. WuXi AppTec

6. 10.6. Catalent, Inc.

7. 10.7. Samsung Biologics

8. 10.8. Fujifilm Diosynth Biotechnologies

9. 10.9. Charles River Laboratories

10. 10.10. Cytiva

11. APPENDIX

1. 11.1. Currency

2. 11.2. Assumptions

3. 11.3. Base and Forecast Years Timeline

4. 11.4. Key benefits for the stakeholders

5. 11.5. Research Methodology

6. 11.6. Abbreviations